Join our community of smart investors

AstraZeneca – positive results with a logistical advantage

The UK pharma heavyweight has delivered positive clinical results for its Covid-19, complete with a significant advantage from a logistical perspective
November 23, 2020
  • Positive phase three clinical trial results - combined efficacy of 70 per cent
  • storage and transportation of the vaccine can be conducted at normal refrigerated conditions
IC TIP: Buy at 8179p

AstraZeneca (AZN), in conjunction with the University of Oxford, has released positive clinical trial results of its Covid-19 vaccine within days of Pfizer (NYSE: PFE) and BioNTech announcing that they were filing for emergency vaccine authorisation from the US Food and Drug Administration for their candidate.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in